Skip to main content
Premium Trial:

Request an Annual Quote

Baypoint Bio Licenses Ovarian, Breast Cancer Dx IP from MD Anderson

NEW YORK (GenomeWeb News) – Baypoint Biosystems said today it has licensed predictive biomarker intellectual property from the University of Texas MD Anderson Cancer Center in Houston.

The privately held company has obtained exclusive, worldwide rights to commercialize certain proteomics IP and clinical biomarkers for predicting therapeutic responses for certain ovarian and breast cancers.

Baypoint Founder and CEO James Erickson said the proteomics technology will provide “our pharmaceutical partners with new insights into how their drugs are working, in which cancers their drugs are most likely to be effective, and how to rationally combine experimental drugs with approved therapeutics.”

Baypoint, which is also based in Houston, is developing predictive tests for ovarian cancer, hormone-dependent breast cancer, HER2-amplified breast cancer and triple receptor-negative breast cancer.

Financial terms of the agreement were not released.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.